Your browser doesn't support javascript.
loading
Cardiac and perivascular myofibroblasts, matrifibrocytes, and immune fibrocytes in hypertension; commonalities and differences with other cardiovascular diseases.
Torimoto, Keiichi; Elliott, Katherine; Nakayama, Yuki; Yanagisawa, Hiromi; Eguchi, Satoru.
Afiliación
  • Torimoto K; Department of Cardiovascular Science, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
  • Elliott K; Department of Cardiovascular Science, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
  • Nakayama Y; Sol Sherry Thrombosis Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
  • Yanagisawa H; Department of Cardiovascular Science, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
  • Eguchi S; Sol Sherry Thrombosis Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
Cardiovasc Res ; 120(6): 567-580, 2024 May 07.
Article en En | MEDLINE | ID: mdl-38395029
ABSTRACT
Hypertension is a major cause of cardiovascular diseases such as myocardial infarction and stroke. Cardiovascular fibrosis occurs with hypertension and contributes to vascular resistance, aortic stiffness, and cardiac hypertrophy. However, the molecular mechanisms leading to fibroblast activation in hypertension remain largely unknown. There are two types of fibrosis replacement fibrosis and reactive fibrosis. Replacement fibrosis occurs in response to the loss of viable tissue to form a scar. Reactive fibrosis occurs in response to an increase in mechanical and neurohormonal stress. Although both types of fibrosis are considered adaptive processes, they become maladaptive when the tissue loss is too large, or the stress persists. Myofibroblasts represent a subpopulation of activated fibroblasts that have gained contractile function to promote wound healing. Therefore, myofibroblasts are a critical cell type that promotes replacement fibrosis. Although myofibroblasts were recognized as the fibroblasts participating in reactive fibrosis, recent experimental evidence indicated there are distinct fibroblast populations in cardiovascular reactive fibrosis. Accordingly, we will discuss the updated definition of fibroblast subpopulations, the regulatory mechanisms, and their potential roles in cardiovascular pathophysiology utilizing new knowledge from various lineage tracing and single-cell RNA sequencing studies. Among the fibroblast subpopulations, we will highlight the novel roles of matrifibrocytes and immune fibrocytes in cardiovascular fibrosis including experimental models of hypertension, pressure overload, myocardial infarction, atherosclerosis, aortic aneurysm, and nephrosclerosis. Exploration into the molecular mechanisms involved in the differentiation and activation of those fibroblast subpopulations may lead to novel treatments for end-organ damage associated with hypertension and other cardiovascular diseases.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fibrosis / Miofibroblastos / Hipertensión Límite: Animals / Humans Idioma: En Revista: Cardiovasc Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fibrosis / Miofibroblastos / Hipertensión Límite: Animals / Humans Idioma: En Revista: Cardiovasc Res Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos